Question to the Department of Health and Social Care:

To ask His Majesty's Government whether they intend to license the drug Lecanemab for the treatment of dementia and Alzheimer’s disease; and if so, when.

The Medicines and Healthcare products Regulatory Agency will review any marketing authorisation application received, and will consider the drug with regard to quality, safety and efficacy. We do not comment on application status or applications in progress, until a full and timely decision is made with consideration of the recommendation of Commission on Human Medicines as needed. We continue to advise that patients consult with their respective healthcare professionals regarding treatment and management options for dementia and Alzheimer’s disease.